London, United Kingdom Nov 13, 2023 (Issuewire.com) - FIECON, a leading life sciences consultancy, is excited to announce a significant expansion of the expertise available to clients in rapid problem-solving for global commercial challenges at executive levels: FIECON Strategic Council.
The FIECON Strategic Council is a powerhouse team of executive leaders, poised to provide clients with unparalleled access to high-calibre expertise across commercial, payer, and patient advocacy. The Strategic Council comprises three eminent experts – Dawn Lee, Eric Low, and Susan Suponcic.
Dawn Lee is a distinguished Associate Professor of Health Economics and Health Policy at the Peninsula Technology Assessment Group (PenTAG). Dawn is a current payer, leading an Evidence Review Group and serving as a NICE committee member. She is an exceptional health economist with a track record of over 50 UK Health Technology Assessment submissions and global expertise spanning more than 30 countries.
Eric Low, OBE is a visionary key opinion leader with an unwavering commitment to patient outcomes and rare diseases' prevention and curability. He is a leading authority in orphan drugs and melanoma medical research, local market access and patient organisations in the UK. Notably, he founded Myeloma UK and currently runs a consultancy specialising in strategic market access, healthcare policy, and patient engagement.
Dr. Susan Suponcic brings a wealth of US and Global pricing and market access commercialisation expertise. Her vast experience across US pharmaceutical companies and global consultancies will be leveraged to provide FIECON clients’ access to specific US launch and commercialisation expertise.
The formation of the council underscores FIECON’s continued commitment to delivering industry-best results, experiences, and partnerships to clients in the pharmaceutical and Medtech industry.
Mark Fisher, CEO of FIECON, explained the vision for the council, "FIECON has redefined the standard of excellence for strategic advice and support for the life sciences industry. Clients can look forward to unprecedented access to these commercialisation titans and an accelerated path to resolving their commercialisation challenges in Global markets, in particular, the dynamic UK and US markets.
The Strategic Council members: Dawn, Eric and Susan will be live at ISPOR Europe in Copenhagen from 13th -15th November. For more information about FIECON and its Strategic Council, please visit FIECON Strategic Council or contact karl.freemyer@fiecon.com to start a commercialisation conversation.
Media Contact
Kate Monk kate.benson@fiecon.com 07711669553 Hodgkin Huxley House, 30 Farringdon Lane, EC1R 2AW http://www.fiecon.com
